Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...
MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...
Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...
New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle regulation theory" of cancer-induced cachexia and anorexia. Cachexia is a ...
Cancer cachexia, or the wasting syndrome, is a catastrophic condition that causes dramatic and involuntary loss of muscle mass, fat and weight, alongside extreme fatigue, anorexia and anemia in ...
London, UK – 9 th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and ...
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...
In cachexia, liver metabolism is fundamentally reprogrammed. One gene, which normally regulates the liver’s activity throughout the day, ceases to function properly. Using a mouse model, the ...
Researchers at the University of Houston are pushing the boundaries of biomedical innovation with a discovery that could transform treatment for one of cancer’s most devastating complications. In a ...
MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results